Bionano Genomics, Inc. (BNGO)
NASDAQ: BNGO · Real-Time Price · USD
1.660
-0.020 (-1.19%)
At close: Dec 11, 2025, 4:00 PM EST
1.670
+0.010 (0.60%)
Pre-market: Dec 12, 2025, 4:33 AM EST
Bionano Genomics Revenue
Bionano Genomics had revenue of $7.37M in the quarter ending September 30, 2025, with 21.31% growth. This brings the company's revenue in the last twelve months to $28.72M, down -13.84% year-over-year. In the year 2024, Bionano Genomics had annual revenue of $30.78M, down -14.79%.
Revenue (ttm)
$28.72M
Revenue Growth
-13.84%
P/S Ratio
0.19
Revenue / Employee
$287,200
Employees
100
Market Cap
16.89M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 30.78M | -5.34M | -14.79% |
| Dec 31, 2023 | 36.12M | 8.31M | 29.90% |
| Dec 31, 2022 | 27.80M | 9.82M | 54.62% |
| Dec 31, 2021 | 17.98M | 9.48M | 111.47% |
| Dec 31, 2020 | 8.50M | -1.63M | -16.06% |
| Dec 31, 2019 | 10.13M | -1.87M | -15.59% |
| Dec 31, 2018 | 12.00M | 2.50M | 26.26% |
| Dec 31, 2017 | 9.51M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
BNGO News
- 8 days ago - Final 2026 Clinical Lab Fee Schedule Indicates a 47% Increase in Payment Determination for the Category I CPT Code for OGM use in Hematologic Malignancies - GlobeNewsWire
- 4 weeks ago - Bionano Genomics, Inc. (BNGO) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 4 weeks ago - Bionano Reports Third Quarter 2025 Results and Highlights Recent Business Progress - GlobeNewsWire
- 5 weeks ago - Bionano Announces Publication Showing OGM Can Overcome Key Limitations of Targeted RNA-Seq for Cytogenetic Investigation in Acute Leukemia - GlobeNewsWire
- 6 weeks ago - Bionano to Report Third Quarter 2025 Financial Results and Host a Conference Call Webcast on November 13, 2025 - GlobeNewsWire
- 2 months ago - Bionano to Participate in the H.C. Wainwright @ Home Event - GlobeNewsWire
- 3 months ago - Nasdaq Surges 100 Points; Bionano Genomics Shares Plunge - Benzinga
- 3 months ago - Bionano Genomics, Inc. Announces Closing of $10 Million Public Offering - GlobeNewsWire